Evidence map›Paper›PMID 36364420›Full record

ReviewMolecules (Basel, Switzerland)2022

Hydrolyzable Tannins in the Management of Th1, Th2 and Th17 Inflammatory-Related Diseases.

Stefano Piazza, Marco Fumagalli, Giulia Martinelli, Carola Pozzoli, Nicole Maranta, Marco Angarano, Enrico Sangiovanni, Mario Dell'Agli

Open access · goldAbstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
6.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Hydroethanolic Extract ofTheScientificWorldJournal · 2025
    Article
  10. International journal of molecular sciences · 2024
    Article
  11. Molecules (Basel, Switzerland) · 2024
    Article
  12. Article
  13. Investigation into the Anti-Acne Effects ofInternational journal of molecular sciences · 2024
    Article
  14. Article
  15. Article
  16. Ellagitannins fromNutrients · 2023
    Article
  17. Association ofFrontiers in pediatrics · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Stefano PiazzaDepartment of Pharmacological and Biomolecular Sciences, University of Milan, 20133 Milan, Italy.ORCID 0000-0002-2470-6038
Marco FumagalliDepartment of Pharmacological and Biomolecular Sciences, University of Milan, 20133 Milan, Italy.
Giulia MartinelliDepartment of Pharmacological and Biomolecular Sciences, University of Milan, 20133 Milan, Italy.ORCID 0000-0002-0742-0521
Carola PozzoliDepartment of Pharmacological and Biomolecular Sciences, University of Milan, 20133 Milan, Italy.
Nicole MarantaDepartment of Pharmacological and Biomolecular Sciences, University of Milan, 20133 Milan, Italy.
Marco AngaranoDepartment of Pharmacological and Biomolecular Sciences, University of Milan, 20133 Milan, Italy.ORCID 0000-0001-8632-4660
Enrico SangiovanniDepartment of Pharmacological and Biomolecular Sciences, University of Milan, 20133 Milan, Italy.ORCID 0000-0003-2811-8628
Mario Dell'AgliDepartment of Pharmacological and Biomolecular Sciences, University of Milan, 20133 Milan, Italy.ORCID 0000-0001-5378-402X
University of Milan · IT

Funding

Ministry of Education, Universities and Research Progetto Eccellenza
6 · The paper itself

Abstract

Plants rich in hydrolyzable tannins were traditionally used all over the world for a variety of chronic inflammatory disorders, including arthritis, colitis, and dermatitis. However, the knowledge of their immunological targets is still limited though fundamental for their rational use in phytotherapy. The recent advances regarding the pathogenesis of inflammatory-based diseases represent an opportunity to elucidate the pharmacological mechanism of plant-derived metabolites with immunomodulatory activity. This review collects recent articles regarding the role of hydrolyzable tannins and their gut metabolites in Th1, Th2, and Th17 inflammatory responses. In line with the traditional use, rheumatoid arthritis (RA), inflammatory bowel diseases (IBDs), psoriasis, atopic dermatitis (AD), and asthma were the most investigated diseases. A substantial body of in vivo studies suggests that, beside innate response, hydrolyzable tannins may reduce the levels of Th-derived cytokines, including IFN-γ, IL-17, and IL-4, following oral administration. The mode of action is multitarget and may involve the impairment of inflammatory transcription factors (NF-κB, NFAT, STAT), enzymes (MAPKs, COX-2, iNOS), and ion channels. However, their potential impact on pathways with renewed interest for inflammation, such as JAK/STAT, or the modulation of the gut microbiota demands dedicate studies.

Indexed as

Arthritis, RheumatoidDermatitis, AtopicCytokinesHumansHydrolyzable TanninsTh17 CellsCytokinesHydrolyzable Tanninsatopic dermatitisellagitanninsgallotanninshydrolyzable tanninsinflammationinflammatory bowel diseasesrheumatoid arthritisTh1Th17Th2

Identifiers

PMID36364420
PMCPMC9655852
OpenAlexW4308476091

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.